Professor Kamlesh Khunti receives prestigious GG2 Outstanding Achievement in Medicine Award

The Leicester Diabetes Centre is delighted to announce that Professor Kamlesh Khunti, Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester and Director of the National Institute for Health and Care Research (NIHR) Applied Research Collaboration (ARC) East Midlands, has been awarded the GG2 Outstanding Achievement in Medicine Award at the GG2 Leadership and Diversity Awards 2026.

This national accolade recognises Professor Khunti’s exceptional contributions to medicine, his leadership in transforming diabetes care, and his commitment to reducing health inequalities. As a co‑founder and Co-Director of the Leicester Diabetes Centre, Professor Khunti has played a pivotal role in establishing world‑leading research programmes and pioneering approaches that have significantly improved outcomes for people living with diabetes across the UK and internationally.

Reflecting on the award, Professor Khunti said:

“I am truly honoured to receive this award. It reflects the work of an incredible team and the support of our patients, our wonderful Leicester Diabetes Centre Team and colleagues nationally and internationally. Our shared goal has always been to improve the lives of people living with cardiometabolic diseases and to tackle the inequalities that so many communities face. I am grateful to everyone who has been part of this journey.”

The GG2 Leadership and Diversity Awards celebrate individuals who champion inclusion and drive positive change. Professor Khunti’s award highlights not only his scientific achievements but also his long‑standing dedication to advancing equitable healthcare for all communities.

We are immensely proud of Professor Khunti’s accomplishments and the far‑reaching impact of his work.

Congratulations, Professor Khunti, on this well‑deserved recognition!

Professor Kamlesh Khunti receiving the GG2 Outstanding Achievement in Medicine Award.


Latest LDC News:

Next
Next

Landmark diabetes trial tests new treatments to bring back ‘hypo’ awareness